Online

WCB 2021 - Online

Session Item

Thursday
May 06
14:15 - 15:30
This house believes that combination therapy for intermediate and high-risk prostate cancer represents best standard of care
Peter Hoskin, United Kingdom;
Yasuo Yoshioka, Japan
0091
Debate
15:00 - 15:15
Against the motion rebuttal: Brachytherapy Boost for Prostate Cancer - A Diminishing Solution
Jarad Martin, Australia
SP-0032

Abstract

Against the motion rebuttal: Brachytherapy Boost for Prostate Cancer - A Diminishing Solution
Authors: Jarad Martin(Calvary Mater Newcastle, Department of Radiation Oncology, Newcastle, Australia), Mark Sidhom(Liverpool Hospital, Department of Radiation Oncology, Sydney, Australia), David Pryor(Princess Alexandra Hospital, Radiation Oncology, Brisbane, Australia), Colin Tang(5D Clinics, Radiation Oncology, Perth, Australia), Amy Hayden(Westmead Hospital, Radiation Oncology, Sydney, Australia), Andrew Miller(Illawarra Cancer Care Centre, Radiation Oncology, Wollongong, Australia), Swetha Sridaran(Calvary Mater Newcastle, Radiation Oncology, Newcastle, Australia), Yuvnik Trada(Calvary Mater Newcastle, Radiation Oncology, Newcastle, Australia), Anne Capp(GenesisCare Gateshead, Radiation Oncology, Newcastle, Australia), Peter Greer(University of Newcastle, Medical Physics, Newcastle, Australia), Paul Keall(University of Sydney, Image X Institute, Sydney, Australia), Shankar Siva(Peter MacCallum Cancer Centre, Radiation Oncology, Melbourne, Australia), Jonathan Tomaszewski(Ballarat Austin Radiation Oncology Centre, Radiation Oncology, Ballarat, Australia)
Show Affiliations
Abstract Text

Prostate cancer dose escalation was pioneered in the 1980s and 90s with brachytherapy.  As external beam approaches have become more sophisticated alongside better functional staging investigations and integration of systemic therapies, the use of brachytherapy has been declining world wide.  Although we recognize the valuable lessons learnt from the brachytherapy literature, the field is evolving in different directions which we will explore in this debate.